Collaboration and License Agreements - Additional Information (Details) |
1 Months Ended | 12 Months Ended | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Nov. 30, 2023
USD ($)
|
Oct. 31, 2023
USD ($)
shares
|
Oct. 31, 2022 |
Sep. 30, 2022
USD ($)
shares
|
Jun. 30, 2022
USD ($)
|
Jan. 31, 2022
USD ($)
|
Dec. 31, 2021
USD ($)
|
Oct. 31, 2021
USD ($)
|
Jul. 31, 2021
USD ($)
|
Jun. 30, 2021
USD ($)
|
Oct. 31, 2020
shares
|
Sep. 30, 2019
USD ($)
shares
|
Apr. 30, 2019
USD ($)
shares
|
Dec. 31, 2023
USD ($)
shares
|
Dec. 31, 2022
USD ($)
|
Dec. 31, 2021
USD ($)
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||||||
| Current portion of deferred revenue | $ 68,706,000 | $ 135,974,000 | ||||||||||||||
| Long-term portion of deferred revenue | 109,888,000 | 202,179,000 | ||||||||||||||
| Deferred revenue liability | $ 348,573,000 | 178,594,000 | 338,153,000 | $ 348,573,000 | ||||||||||||
| Research and development expense | 437,381,000 | 311,594,000 | 387,087,000 | |||||||||||||
| Gain (loss) from equity method investment | (25,500,000) | |||||||||||||||
| License revenue | 377,709,000 | 60,920,000 | 51,844,000 | |||||||||||||
| Carrying value of equity method investment | $ 0 | 0 | ||||||||||||||
| Verve Therapeutics, Inc. | Common Stock | ||||||||||||||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||||||
| Equity shares held | shares | 546,970 | |||||||||||||||
| Lilly Agreement | ||||||||||||||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||||||
| Proceeds from potential future development-stage upfront payments | $ 200,000,000 | |||||||||||||||
| Sale and issuance of common stock | shares | 2,004,811 | |||||||||||||||
| Aggregated purchase price | $ 50,000,000 | |||||||||||||||
| Stock purchase agreement amount received | 50,000,000 | |||||||||||||||
| Fair value of common stock sold | 16,400,000 | |||||||||||||||
| Collaboration agreement upfront payment received | $ 200,000,000 | |||||||||||||||
| Collaboration agreement performance obligation revenue recognized | $ 216,400,000 | |||||||||||||||
| License agreement upfront payment received | 200,000,000 | |||||||||||||||
| Collaboration agreement aggregate transaction price | $ 216,400,000 | |||||||||||||||
| Collaboration agreement term of contract | 6 years | |||||||||||||||
| Deferred revenue liability | 0 | |||||||||||||||
| Collaboration license agreement fair value of shares issued | $ 33,600,000 | |||||||||||||||
| Lilly Agreement | Maximum | ||||||||||||||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||||||
| Additional proceeds from potential future development-stage payments | 350,000,000 | |||||||||||||||
| Pfizer | ||||||||||||||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||||||
| Agreement description | In December 2021, the Company entered into a research collaboration agreement, or the Pfizer Agreement, with Pfizer Inc., or Pfizer, focused on the use of certain of the Company’s base editing technology to develop in vivo therapies for rare genetic diseases of the liver, muscle, and central nervous system. Under the terms of the Pfizer Agreement, the Company will conduct all research activities through development candidate selection for three base editing programs that target specific genes corresponding to specific diseases that are the subject of such programs. Pfizer will have exclusive rights to license each of the three programs at no additional cost, each an Opt-In Right, and will assume responsibility for subsequent development and commercialization. At the end of the Phase 1/2 clinical trials, the Company may elect to enter into a global co-development and co-commercialization agreement with Pfizer with respect to one program licensed under the collaboration for an option exercise fee equal to a percentage of the applicable development costs incurred by Pfizer, or the Participation Election. In the event the Company elects to exercise its Participation Election, upon the payment of its option exercise fee, Pfizer and the Company would share net profits as well as development and commercialization costs in a 65%/35% (Pfizer/Company) split for such program. The research collaboration is managed on an overall basis by a Joint Research Committee, or JRC, formed by an equal number of representatives from the Company and Pfizer. | |||||||||||||||
| Collaboration arrangement, initial term | 4 years | |||||||||||||||
| Collaboration arrangement extension term description | extended for an additional year on a program-by-program basis | |||||||||||||||
| Potential total consideration | $ 1,350,000,000 | 1,350,000,000 | ||||||||||||||
| Nonrefundable upfront payment receivable | 300,000,000 | 300,000,000 | ||||||||||||||
| Collaboration agreement upfront payment received | $ 300,000,000 | |||||||||||||||
| Collaboration agreement performance obligation revenue recognized | 134,300,000 | 48,200,000 | 0 | |||||||||||||
| Collaboration agreement aggregate transaction price | $ 300,000,000 | 300,000,000 | ||||||||||||||
| Current portion of deferred revenue | 42,900,000 | |||||||||||||||
| Long-term portion of deferred revenue | 74,600,000 | |||||||||||||||
| Earn-out payment period | 10 years | |||||||||||||||
| Deferred revenue liability | $ 300,000,000 | $ 300,000,000 | ||||||||||||||
| Pfizer | Assigned to Company | Upon Participation Election | ||||||||||||||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||||||
| Net profits as well as development and commercialization costs percentage | 35.00% | 35.00% | ||||||||||||||
| Pfizer | Assigned to Pfizer | Upon Participation Election | ||||||||||||||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||||||
| Net profits as well as development and commercialization costs percentage | 65.00% | 65.00% | ||||||||||||||
| Pfizer | Maximum | Per Program | ||||||||||||||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||||||
| Development regulatory and commercial milestones receivable | $ 350,000,000 | $ 350,000,000 | ||||||||||||||
| Sana Biotechnology | ||||||||||||||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||||||
| Collaboration agreement performance obligation revenue recognized | 1,800,000 | 50,000,000 | ||||||||||||||
| License agreement upfront payment received | $ 50,000,000 | |||||||||||||||
| Collaboration agreement aggregate transaction price | 50,000,000 | |||||||||||||||
| Additional fee per additional option right | 10,000,000 | |||||||||||||||
| Option rights aggregate potential additional consideration | 20,000,000 | |||||||||||||||
| Sana Biotechnology | Maximum | ||||||||||||||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||||||
| Development regulatory and commercial milestones receivable | $ 65,000,000 | |||||||||||||||
| Sana Biotechnology | License Agreement Terms | ||||||||||||||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||||||
| Agreement description | For up to thirty months following the effective date of the Sana Agreement, Sana has the option to select up to a cumulative total of two additional CAR antigen targets or PSC product types for an additional fee of $10.0 million per additional CAR antigen target and additional PSC product type, or the Option Rights, for an aggregate potential additional consideration of $20.0 million. Further, for up to thirty months following the effective date of the Sana Agreement, Sana has a one-time right to substitute, in the aggregate, either one CAR antigen target or one PSC product type at no additional cost, or the Replacement Right. Sana may also select a specified number of additional or replacement genetic targets for each PSC product type at any time prior to the third anniversary of the effective date at no additional cost, or the Genetic Target Nomination Rights. Sana may terminate the Sana Agreement for convenience prior to the first commercial sale of any licensed product by providing 90 days’ prior written notice or upon 180 days’ prior written notice after first commercial sale. | |||||||||||||||
| Apellis Pharmaceuticals, Inc | ||||||||||||||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||||||
| Agreement description | In June 2021, the Company entered into a research collaboration agreement, or the Apellis Agreement, with Apellis Pharmaceuticals, Inc., or Apellis, focused on the use of certain of the Company’s base editing technology to discover new treatments for complement system-driven diseases. Under the terms of the Apellis Agreement, the Company will conduct preclinical research on up to six base editing programs that target specific genes within the complement system in various organs, including the eye, liver, and brain. Apellis has an exclusive option to license any or all of the six programs, or in each case, an Opt-In Right, and will assume responsibility for subsequent development. The Company may elect to enter into a 50-50 U.S. co-development and co-commercialization agreement with Apellis with respect to one program instead of a license. The collaboration is managed on an overall basis by an alliance steering committee formed by an equal number of representatives from the Company and Apellis. | |||||||||||||||
| Collaboration arrangement, initial term | 5 years | |||||||||||||||
| Upfront revenue recognized | $ 0 | |||||||||||||||
| Collaboration agreement performance obligation revenue recognized | 16,400,000 | 10,600,000 | 1,800,000 | |||||||||||||
| Collaboration agreement aggregate transaction price | 75,000,000 | |||||||||||||||
| Upfront fee receivable upon signing contract | 50,000,000 | |||||||||||||||
| Collaboration agreement first anniversary amount receivable | $ 25,000,000 | $ 25,000,000 | ||||||||||||||
| Upfront payment received under term of agreement | $ 50,000,000 | |||||||||||||||
| Collaboration agreement first anniversary payment received | $ 25,000,000 | |||||||||||||||
| Current portion of deferred revenue | 17,300,000 | |||||||||||||||
| Long-term portion of deferred revenue | $ 28,900,000 | |||||||||||||||
| Apellis Pharmaceuticals, Inc | Maximum | ||||||||||||||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||||||
| Collaboration arrangement extension term | 2 years | |||||||||||||||
| Prime Medicine Inc | ||||||||||||||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||||||
| Collaborative arrangement rights and obligations, description | The Company had an obligation to issue $5.0 million in shares of its common stock to Prime Medicine, and Prime Medicine had an obligation to issue 5,000,000 shares of its common stock to the Company, should the Company elect to extend the collaboration beyond one year | |||||||||||||||
| Obligation to issue common stock value | $ 5,000,000 | |||||||||||||||
| Obligation to issue common stock shares | shares | 5,000,000 | |||||||||||||||
| Reverse stock split ratio | 3.1088 | |||||||||||||||
| Reverse stock split | one-for-3.1088 | |||||||||||||||
| Equity shares held | shares | 1,608,337 | |||||||||||||||
| Prime Medicine Inc | Common Stock | ||||||||||||||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||||||
| Shares issued and sold | shares | 200,307 | |||||||||||||||
| Number of common stock received | shares | 5,000,000 | |||||||||||||||
| Equity shares held | shares | 1,608,337 | |||||||||||||||
| Equity shares value held | $ 14,200,000 | |||||||||||||||
| Verve | ||||||||||||||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||||||
| Remaining unrecognized revenue recognized | $ 300,000 | |||||||||||||||
| Deferred revenue liability | 0 | |||||||||||||||
| Upfront payment fair value shares received | $ 500,000 | |||||||||||||||
| License revenue | 400,000 | 24,000 | $ 24,000 | |||||||||||||
| Reverse stock split ratio | 9.2592 | |||||||||||||||
| Reverse stock split | one-for-9.2592 | |||||||||||||||
| Equity shares value held | 7,600,000 | |||||||||||||||
| Verve | Common Stock | ||||||||||||||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||||||
| Collaboration license agreement fair value of shares received | $ 500,000 | |||||||||||||||
| Number of common stock received | shares | 2,600,000 | |||||||||||||||
| Orbital | ||||||||||||||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||||||
| Common stock shares received at closing | shares | 75,000,000 | |||||||||||||||
| Agreement description | Under the terms of the Orbital Agreement, the Company will collaborate with Orbital to advance nonviral delivery and ribonucleic acid, or RNA, technology by providing Orbital with certain proprietary materials, a non-exclusive research license to certain RNA technology and nonviral delivery technology controlled by the Company, and by performing research and development support services as outlined in a research plan. The Company also granted Orbital an exploitation license to certain RNA technology and nonviral delivery technology controlled by the Company. The exploitation license is exclusive in the fields of vaccines and certain protein therapeutics and nonexclusive in all other fields other than gene editing and conditioning. The collaboration is managed on an overall basis by a Joint Steering Committee, or JSC, comprised of an equal number of representatives from the Company and Orbital. | |||||||||||||||
| Collaboration agreement performance obligation revenue period for recognition | 3 years | |||||||||||||||
| Collaboration agreement aggregate transaction price | $ 25,500,000 | |||||||||||||||
| Collaboration agreement performance obligation revenue recognized | 8,500,000 | 2,100,000 | ||||||||||||||
| Collaboration agreement aggregate transaction price | 25,500,000 | |||||||||||||||
| Current portion of deferred revenue | 8,500,000 | |||||||||||||||
| Long-term portion of deferred revenue | 6,400,000 | |||||||||||||||
| Gain (loss) from equity method investment | $ 0 | $ (25,500,000) | ||||||||||||||
| Carrying value of equity method investment | $ 0 | |||||||||||||||
| Orbital | Research Plan | ||||||||||||||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||||||
| Collaboration arrangement, initial term | 3 years | |||||||||||||||
| Orbital | Exploitation Licenses | ||||||||||||||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||||||
| Collaboration arrangement, initial term | 3 years | |||||||||||||||
| Collaboration arrangement extension term description | which may be extended for up to two successive one-year periods | |||||||||||||||
| Orbital | Option Pricing Model | Level 3 | Volatility of Market Participants | ||||||||||||||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||||||
| Alternate investment, measurement input | 0.68 | |||||||||||||||
| Orbital | Option Pricing Model | Level 3 | Discount for Lack of Marketability | ||||||||||||||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||||||
| Alternate investment, measurement input | 0.43 | |||||||||||||||